{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:52:39Z","timestamp":1791229959084,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00467-024-06530-2","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T23:32:12Z","timestamp":1728430332000},"page":"1041-1047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody\u2013mediated hemolytic uremic syndrome"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-6847","authenticated-orcid":false,"given":"Paula A.","family":"Coccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-0307","authenticated-orcid":false,"given":"Laura F.","family":"Alconcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-5835","authenticated-orcid":false,"given":"Veronica","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1008-0540","authenticated-orcid":false,"given":"Lucas I.","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8078-7037","authenticated-orcid":false,"given":"Maria A.","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Andrea","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Saurit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana M.","family":"Ratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0431-1004","authenticated-orcid":false,"given":"Celia","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-9217","authenticated-orcid":false,"given":"Anal\u00eda","family":"S\u00e1nchez-Luceros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"6530_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1681\/ASN.2004100861","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035\u20131050. https:\/\/doi.org\/10.1681\/ASN.2004100861","journal-title":"J Am Soc Nephrol"},{"key":"6530_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00431-015-2642-1","volume":"175","author":"G Ardissino","year":"2016","unstructured":"Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N et al (2016) Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr 175:465\u2013473. https:\/\/doi.org\/10.1007\/s00431-015-2642-1","journal-title":"Eur J Pediatr"},{"key":"6530_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 13:300\u2013317. https:\/\/doi.org\/10.2215\/CJN.00620117","journal-title":"Clin J Am Soc Nephrol"},{"key":"6530_CR4","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","volume":"10","author":"M Puraswani","year":"2019","unstructured":"Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS et al (2019) Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database. Front Immunol 10:1282. https:\/\/doi.org\/10.3389\/fimmu.2019.01282","journal-title":"Front Immunol"},{"key":"6530_CR5","doi-asserted-by":"publisher","unstructured":"Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD et al (2017) Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 92:1261\u20131271. https:\/\/doi.org\/10.1016\/j.kint.2017.04.028","DOI":"10.1016\/j.kint.2017.04.028"},{"key":"6530_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","volume":"219","author":"R Watson","year":"2014","unstructured":"Watson R, Lindner S, Bordereau P, Hunze EM, Tak F et al (2014) Standardization of the factor H autoantibody assay. Immunobiology 219:9\u201316. https:\/\/doi.org\/10.1016\/j.imbio.2013.06.004","journal-title":"Immunobiology"},{"key":"6530_CR7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A et al (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151\u20131160. https:\/\/doi.org\/10.1038\/ki.2013.373","journal-title":"Kidney Int"},{"key":"6530_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","volume":"29","author":"D Noone","year":"2014","unstructured":"Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M et al (2014) Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 29:841\u2013851. https:\/\/doi.org\/10.1007\/s00467-013-2654-x","journal-title":"Pediatr Nephrol"},{"key":"6530_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00467-017-3612-9","volume":"32","author":"A Hackl","year":"2017","unstructured":"Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB et al (2017) Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol 32:1081\u20131087. https:\/\/doi.org\/10.1007\/s00467-017-3612-9","journal-title":"Pediatr Nephrol"},{"key":"6530_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-62703-724-2_20","volume":"1100","author":"MA Dragon-Durey","year":"2014","unstructured":"Dragon-Durey MA, Blanc C, Roumenina LT, Poulain N, Ngo S et al (2014) Anti-factor H autoantibodies assay. Methods Mol Biol 1100:249\u2013256. https:\/\/doi.org\/10.1007\/978-1-62703-724-2_20","journal-title":"Methods Mol Biol"},{"key":"6530_CR11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2215\/CJN.00320116","volume":"11","author":"S Tellier","year":"2016","unstructured":"Tellier S, Dallocchio A, Guigonis V et al (2016) Mycophenolic acid pharmacokinetics and relapse in children with steroid\u2013dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 11:1777\u20131782. https:\/\/doi.org\/10.2215\/CJN.00320116","journal-title":"Clin J Am Soc Nephrol"},{"key":"6530_CR12","doi-asserted-by":"publisher","first-page":"931210","DOI":"10.3389\/fimmu.2022.931210","volume":"13","author":"R Raina","year":"2022","unstructured":"Raina R, Mangat G, Hong G, Shah R, Nair N et al (2022) Anti-factor H antibody and its role in atypical hemolytic uremic syndrome. Front Immunol 13:931210. https:\/\/doi.org\/10.3389\/fimmu.2022.931210","journal-title":"Front Immunol"},{"key":"6530_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2215\/CJN.01260212","volume":"8","author":"J Hofer","year":"2013","unstructured":"Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A et al (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407\u2013415. https:\/\/doi.org\/10.2215\/CJN.01260212","journal-title":"Clin J Am Soc Nephrol"},{"key":"6530_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.37349\/ei.2023.00118","volume":"3","author":"C Dos Santos","year":"2023","unstructured":"Dos Santos C, Trinidad J, Castera S, Alconcher L, Coccia PA et al (2023) Anti-factor H autoantibody associated hemolytic uremic syndrome in an Argentine pediatric cohort. Explor Immunol 3:513\u2013524. https:\/\/doi.org\/10.37349\/ei.2023.00118","journal-title":"Explor Immunol"},{"key":"6530_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M et al (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"6530_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi CP et al (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91:539\u2013551. https:\/\/doi.org\/10.1016\/j.kint.2016.10.005","journal-title":"Kidney Int"},{"key":"6530_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.5005\/jp-journals-10071-23985","volume":"25","author":"S \u00d6zsoylu","year":"2021","unstructured":"\u00d6zsoylu S, Dursun A, \u00c7elik B (2021) Therapeutic plasma exchange in pediatric intensive care unit: a single-center experience. Indian J Crit Care Med 25:1189\u20131192. https:\/\/doi.org\/10.5005\/jp-journals-10071-23985","journal-title":"Indian J Crit Care Med"},{"key":"6530_CR18","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00467-021-05025-8","volume":"36","author":"L Matrat","year":"2021","unstructured":"Matrat L, Bacchetta J, Ranchin B, Tann\u00e9 C, Sellier-Leclerc AL et al (2021) Pediatric atypical hemolytic-uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil? Pediatr Nephrol 36:1647\u20131650. https:\/\/doi.org\/10.1007\/s00467-021-05025-8","journal-title":"Pediatr Nephrol"},{"key":"6530_CR19","doi-asserted-by":"publisher","unstructured":"Ferri M, Zotta F, Donadelli R, Dossier C, Duneton C et al (2024) Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange? Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-024-06373-x","DOI":"10.1007\/s00467-024-06373-x"},{"key":"6530_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","volume":"100","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T et al (2021) The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment. Kidney Int 100:225\u2013237. https:\/\/doi.org\/10.1016\/j.kint.2020.10.046","journal-title":"Kidney Int"},{"key":"6530_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F et al (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64:633\u2013637. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434","journal-title":"Am J Kidney Dis"},{"key":"6530_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2022","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, van der Heijden JW et al (2022) Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS Study. Kidney Int Rep 8:91\u2013102. https:\/\/doi.org\/10.1016\/j.ekir.2022.10.013","journal-title":"Kidney Int Rep"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06530-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06530-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06530-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:48:50Z","timestamp":1741250930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06530-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6530"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06530-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4492192\/v1","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained via the ethics committee of Hospital Italiano de Buenos Aires. Due to the retrospective nature and because the study involved chart review of children admitted within the study period to the institutions who have been already discharged, the study received a waiver for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}